Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention

References

• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. Jama. 1999;282(24):2340–2346.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Navarese EP, Tantry US. Exploration of PCSK9 as a Cardiovascular Risk Factor: is there a link to the platelet? J Am Coll Cardiol. 2017;70(12):1463–1466.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Winter MP, et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol. 2017;227:644–649.
   PubMed Web of Science ®Google Scholar
• Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602–18612.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Dimitroulis D, et al. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. European Heart Journal. Cardiovascular Pharmacotherapy. 2016;2(1):44–53.
   PubMed Web of Science ®Google Scholar
• Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–146.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40–51.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399–2407.
   PubMed Web of Science ®Google Scholar
• Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Med. 2005;118(Suppl 12A):22–27.
   PubMedGoogle Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama. 2006;295(13):1556–1565.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Li L, et al. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016;25(5):459–465.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061–1068.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama. 2016;316(22):2373–2384.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (London, England). 2013;382(9892):614–623.
   PubMed Web of Science ®Google Scholar
• Pawlowska Z, Swiatkowska M, Krzeslowska J, et al. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis. 1993;103(1):13–20.
   PubMed Web of Science ®Google Scholar
• Naseem KM, Goodall AH, Bruckdorfer KR. Differential effects of native and oxidatively modified low-density lipoproteins on platelet function. Platelets. 1997;8(2–3):163–173.
   PubMed Web of Science ®Google Scholar
• Korporaal SJ, Van Eck M, Adelmeijer J, et al. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2007;27(11):2476–2483.
   PubMed Web of Science ®Google Scholar
• Atar D, Bode C, Stuerzenbecher A, et al. Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. Fundam Clin Pharmacol. 2014;28(4):353–363.
   PubMed Web of Science ®Google Scholar
• Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9(9):e106294.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu J, Li S, et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord. 2014;14:192.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kowalewski M, Kandzari D, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart. 2014;1(1):e000064.
   PubMedGoogle Scholar
• Bavishi C, Trivedi V, Singh M, et al. Duration of dual antiplatelet therapy in patients with an acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2017;130(11):1325.e1321–5.e1312.
   Web of Science ®Google Scholar
• Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2009;30(6):655–661.
   PubMed Web of Science ®Google Scholar
• Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200–1206.
   PubMed Web of Science ®Google Scholar
• Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49(12):1362–1368.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (London, England). 2013;382(9906):1714–1722.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. Bmj. 2015;350:h1618.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003;108(1):2–5.
   PubMed Web of Science ®Google Scholar
• Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation. 2009;120(20):1987–1995.
   PubMed Web of Science ®Google Scholar
• Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. Int J Pharm. 2013;441(1–2):665–679.
   PubMed Web of Science ®Google Scholar
• Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769–1776.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Rutledge JC, Rogers JH. Coronary artery revascularization in patients with diabetes mellitus. Circulation. 2013;128(15):1675–1685.
   PubMed Web of Science ®Google Scholar
• Jung JH, Tantry US, Gurbel PA, et al. Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J. 2015;39(2):95–113.
   PubMed Web of Science ®Google Scholar
• Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000;36(2):355–365.
   PubMed Web of Science ®Google Scholar
• Gleissner CA, Von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol. 2008;28(11):1920–1927.
   PubMed Web of Science ®Google Scholar
• Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32(4):525–527.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e89S–e119S.
   PubMed Web of Science ®Google Scholar
• Fox KA, Anderson FA Jr., Goodman SG, et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med. 2008;5(9):580–589.
   PubMedGoogle Scholar
• Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med. 2013;158(4):261–270.
   PubMed Web of Science ®Google Scholar
• Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13–18.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Yasuda S, Noguchi T, et al. Pathology of coronary atherosclerosis and thrombosis. Cardiovascular Diagnosis and Therapy. 2016;6(4):396–408.
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–235.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016;164(9):600–607.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RM, Nahrendorf M, Riksen NP, et al. Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. Eur Heart J. 2017;ehx581. doi: 10.1093/eurheartj/ehx581/4563761.
   Google Scholar
• Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117–122.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu S, Wang X, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107(4):556–567.
   PubMed Web of Science ®Google Scholar
• Shen L, Peng HC, Nees SN, et al. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Lett. 2013;587(9):1271–1274.
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–386.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363–2372.
   PubMed Web of Science ®Google Scholar
• Wu CY, Tang ZH, Jiang L, et al. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem. 2012;359(1–2):347–358.
   PubMed Web of Science ®Google Scholar
• Kuhnast S, Van Der Hoorn JW, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103–2112.
   PubMed Web of Science ®Google Scholar
• Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297–301.
   PubMed Web of Science ®Google Scholar
• Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–1898.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Focused update of the 2016 acc expert consensus decision pathway on the role of non-statin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785–1822.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–689.
   PubMed Web of Science ®Google Scholar
• Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention. ClinicalTrials.gov Identifier: NCT03258281.
   Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: a Systematic Review and Meta-analysis. Jama. 2018;319(15):1566–1579.
   PubMed Web of Science ®Google Scholar